

LETTER TO THE EDITOR

Open Access



Reply to: High levels of plasma biomarkers at 24 h were found to be strong predictors of 90-day mortality: beware of some potential confounders!

Toni Jääntti^{1*} , Veli-Pekka Harjola², Mikko Haapio³ and Johan Lassus¹

To the Editor,

We wish to thank Honore et al. [1] for their interest in our article [2] and raising a caveat concerning the possible effect of renal replacement therapy (RRT) on proenkephalin (P-PENK) and neutrophil gelatinase-associated lipocalin (P-NGAL) levels in plasma. As suggested by Honore et al., this confounding could lead to an underestimation of the association of early P-PENK and P-NGAL levels with mortality so that if true, the association described in our article could in reality be even stronger. However, as the removal of solutes by RRT is affected also by factors other than molecular weight (such as charge, albumin binding capability, the type of membrane and RRT technique used) whether a molecule is removed from plasma by RRT and to which extent is difficult to predict and should be empirically tested. One small study performed in septic patients with AKI did not detect NGAL (or KIM-1) in the dialysate of continuous RRT [3], but data on the effect of RRT on plasma levels of the biomarkers in our study are mostly lacking.

In our study the time of onset of RRT was recorded in 17/22 patients and only 7 patients (5% of all patients included in our study) had RRT performed within 24 h of

study baseline. Considering the small number of patients in the study who had RRT within 24 h of baseline, we believe that this would not affect the overall results.

Specifically for patients undergoing continuous RRT, using P-PENK, P-NGAL or any other biomarker that could be removed from circulation by RRT as a risk marker might lead to an underestimation of risk and should be interpreted with caution. We completely agree with Honore et al. that studies assessing the performance of prognostic biomarkers in this specific patient group are lacking and should be targeted for future studies.

Abbreviations

P-PENK: Plasma proenkephalin; P-NGAL: Plasma neutrophil gelatinase-associated lipocalin; RRT: Renal replacement therapy.

Acknowledgements

None.

Authors' contributions

TJ, VPH, JL designed the paper. All authors participated in drafting and reviewing. All authors read and approved the final version of the manuscript.

Funding

None.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

This reply refers to the comment available online at <https://doi.org/10.1186/s13613-021-00838-0>.

*Correspondence: toni.jantti@fimnet.fi

¹ Department of Cardiology, Heart and Lung Center, University of Helsinki, Helsinki University Hospital, HUS, 00029 Helsinki, Finland

Full list of author information is available at the end of the article



© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Consent for publication

Not applicable.

Competing Interests

TJ: no competing interests. VPH: advisory board fees from Roche Diagnostics, research grant from Abbott, speaker fees from Orion. MH: no competing interests. JL: speakers bureau and consultancy fees from Astra-Zeneca, Bayer, Boehringer-Ingelheim, Novartis, Orion, Pfizer, Roche Diagnostics, and ViforPharma.

Author details

¹ Department of Cardiology, Heart and Lung Center, University of Helsinki, Helsinki University Hospital, HUS, 00029 Helsinki, Finland. ² Department of Emergency Medicine and Services, University of Helsinki, Helsinki University Hospital, Helsinki, Finland. ³ Department of Nephrology, Abdominal Center, University of Helsinki, Helsinki University Hospital, Helsinki, Finland.

Received: 7 March 2021 Accepted: 10 March 2021

Published online: 15 March 2021

References

1. Honore P, Redant S, Preseau T, Kaefer K, Gutierrez L, Attou R, et al. High levels of plasma biomarkers at 24 h were found to be strong predictors of 90-day mortality: beware of some potential confounders! *Ann Intensive Care*. 2021. <https://doi.org/10.1186/s13613-021-00838-0>.
2. Jääntti T, Tarvasmäki T, Harjola VP, Pulkki K, Turkia H, Sabell T, et al. Predictive value of plasma proenkephalin and neutrophil gelatinase-associated lipocalin in acute kidney injury and mortality in cardiogenic shock. *Ann Intensive Care*. 2021;11(1):25. <https://doi.org/10.1186/s13613-021-00814-8>.
3. Shao Y, Fan Y, Xie Y, Yin L, Zhang Y, Deng L, et al. Effect of continuous renal replacement therapy on kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin in patients with septic acute kidney injury. *Exp Ther Med*. 2017;13(6):3594–602. <https://doi.org/10.3892/etm.2017.4436>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen[®] journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► [springeropen.com](https://www.springeropen.com)
